Call for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection

Abstract

EditorialThe Pathophysiology of COVID-19 and SARS-CoV-2 InfectionCall for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 InfectionRory E. Morty and John ZiebuhrRory E. MortyDepartment of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, GermanyDepartment of Internal Medicine (Pulmonology), University of Giessen and Marburg Lung Center, Justus Liebig University Giessen, member of the German Center for Lung Research, Giessen, Germany and John ZiebuhrInstitute of Medical Virology, Justus Liebig University Giessen, member of the German Center for Infection Research, Giessen, GermanyPublished Online:04 May 2020https://doi.org/10.1152/ajplung.00136.2020This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationSectionsGRANTSDISCLOSURESAUTHOR CONTRIBUTIONSACKNOWLEDGMENTSAUTHOR NOTESPDF (103 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookXLinkedInWeChat The world now finds itself in the grip of a coronavirus pandemic. This is our third brush with a newly emerging zoonotic coronavirus since the turn of the millennium. The first of these three episodes started as an epidemic of severe respiratory disease of zoonotic origin that emerged in November 2002 in Foshan, Guangdong Province, People's Republic of China (41, 42). During the ensuing epidemic, the disease, subsequently named severe acute respiratory syndrome (SARS) (38), was diagnosed in 8,422 patients, and caused 774 deaths in 26 countries spanning five continents. The etiological agent of SARS was identified as a novel coronavirus (12, 17, 18), the SARS coronavirus (SARS-CoV), which is a member of the species Severe acute respiratory syndrome-related coronavirus in the genus Betacoronavirus (9, 13). The SARS epidemic ended on 5 July 2003 (37), and since 2005, no human cases of SARS have been reported (11). The current virus classification collects 39 species into the family Coronaviridae, with 10 more coronavirus species expected to be recognized shortly (13). Coronaviruses are enveloped positive-strand RNA viruses that infect vertebrates (19). Coronaviruses have been known since the 1930s, when infectious bronchitis virus was identified (6) as the cause of an earlier outbreak of highly contagious respiratory disease in chickens in 1931 (26). Subsequently, coronaviruses were identified in mice and pigs in the 1940s (20), and then in humans, when in 1965, 1966, and 1967 three groups of investigators isolated or passaged viruses isolated from human adults with common cold (14, 21, 29, 30). Electron microscopy studies revealed the similarity of these agents associated with common cold in humans to the infectious bronchitis virus of chickens (5) and mouse hepatitis virus (4). Based on the crown ("corona")-like appearance of the surface projections of the virions visualized by electron microscopy, this group of viruses was then named coronaviruses (4, 28). The four endemic human coronaviruses (229E, NL63, OC43, HKU1) are generally associated with upper (rarely, also lower) respiratory tract disease (31). Since the SARS epidemic of 2002–2003, coronaviruses have gone on to cause other severe respiratory disease in two separate outbreaks in humans. The first of these emerged in June 2012 in an adult patient in Jeddah, Saudi Arabia, who died of progressive respiratory and renal failure 11 days after hospital admission for respiratory symptoms (39). A novel coronavirus was subsequently isolated from that patient (39), and was named Middle East respiratory syndrome coronavirus (MERS-CoV) (10) by the Coronaviridae Study Group (CSG), a working group of the International Committee on Taxonomy of Viruses (ICTV) that bears responsibility for the taxonomy and classification of viruses in the family Coronaviridae (13). MERS-CoV is the prototype of the species Middle East respiratory syndrome-related coronavirus (44). Within three years of the appearance of the first MERS patient (thus, by 31 May 2015), 1,180 cases of MERS and 483 deaths had been reported to the World Health Organization (WHO) (45). By the end of 2019, 2,499 MERS cases and 858 deaths had been reported to the WHO since the start of the epidemic, from a total of 27 countries (23). The MERS epidemic remains ongoing. In December 2019, a number of pneumonia cases of unknown cause emerged in Wuhan, Hubei province, People's Republic of China, which exhibited a clinical presentation indicative of viral pneumonia (15). The causative agent was identified as a novel coronavirus that was provisionally named 2019-nCoV (43), which was subsequently allocated as another member of the species Severe acute respiratory syndrome-related coronavirus (19). Based on its close genetic relationship to SARS-CoV (and a large number of "SARS-like" animal coronaviruses isolated primarily from bats), the novel coronavirus was named SARS-CoV-2 by the CSG-ICTV (13). The disease caused by SARS-CoV-2 in humans was named by the WHO as "coronavirus disease 2019," in short, COVID-19 (34). Within three months of the appearance of the first COVID-19 clinical cases in Wuhan, the epidemic rapidly spread to include 143 countries, leading the WHO to declare the COVID-19 situation as a pandemic on 11 March 2020 (7). By 2 April 2020, 896,450 COVID-19 cases and 45,525 deaths had been reported globally (35). MERS and SARS (22), and now also COVID-19 (36), appear on the list of 12 diseases identified by the WHO as priority diseases that are considered to pose the greatest public health risk, either due to their epidemic potential, or where there is (also) insufficient available countermeasures. While closely related to SARS and MERS, COVID-19 exhibits a number of peculiar epidemiological, clinical, and pathogenesis characteristics that remain poorly understood. While SARS-CoV-2 appears to be more easily transmitted than SARS-CoV or MERS-CoV, the fatality rate of COVID-19 (≈2.3%) is lower than that of SARS (≈9.5%) or MERS (≈34.4%) (25). Furthermore, early data suggest that the elderly and those with underlying health conditions, including diabetes mellitus, chronic lung disease, and cardiovascular disease, are at higher risk (8). Thus, the rapidly developing COVID-19 pandemic has underscored the need for accelerated research at several levels, including public health, behavior and education, as well as basic, clinical, and translational science. To address this, the WHO convened a two-day meeting on 11–12 February 2020, the primary (immediate) goal of which was to "accelerate research that can contribute to containing the spread of this epidemic and facilitate that those affected receive optimal care." A secondary (mid-long term) goal was to "support research priorities in a way that leads to the development of global research platforms, aiding preparedness for the next unforeseen epidemic and encouraging accelerated research, development and equitable access, based on public health needs, to diagnostics, therapeutics and vaccines." As a conclusion of that meeting, the WHO published a report in the form of a global research roadmap (33), which highlighted research priorities to respond to the current COVID-19 pandemic. This roadmap highlighted a number of research areas of interest to contributors to our Journal, including studies on SARS-CoV-2 natural history (host species restriction and transmission, environmental stability of viruses, virus compartments of replication, and the duration of shedding). Additionally, studies on clinical aspects of COVID-19 were also recommended (delineation of clinical characteristics of disease; pathophysiology of severe disease; and identifying patient risk groups as well as biomarkers and surrogate markers of infection). Further recommendations included preclinical studies on the development of appropriate animal models, the development of vaccines, studies on the immune modulation of disease, as well as the development of therapeutics. The American Journal of Physiology–Lung Cellular and Molecular Physiology—together with our American Physiological Society sister journals—has already begun contributing scientific reports and thoughtful discussion to these pressing issues. These contributions include reports on virus-host interactions, such as those mediated by angiotensin-converting enzyme 2 (1, 2, 16, 27, 32); as well as consideration of elevated plasmin(ogen) as a risk factor for COVID-19 susceptibility. Additionally, how diabetes modulates the host-viral interactions and host-immune responses in COVID-19 and other coronavirus infections (24), and related renal injury and COVID-19 (40), has received attention, together with the use of artificial intelligence and machine learning to fight COVID-19 (3). However, to accelerate these efforts, the American Journal of Physiology–Lung Cellular and Molecular Physiology together with our sister journal Physiological Reports is issuing a joint Call for Papers on any aspect of COVID-19 pathophysiology as well as SARS-CoV-2-encoded factors affecting disease progression and outcome (https://journals.physiology.org/calls). This Call particularly encourages the submission of manuscripts on the following themes:The development of in vitro, ex vivo, and in vivo (animal) models of SARS-CoV-2 (and other coronavirus) infection(s). These studies may be submitted to our Journal's Innovative Methodology category of manuscripts.The identification of biomarkers that reveal or allow the monitoring of physiological processes at play during SARS-CoV-2 (and other human coronavirus) infections, either in clinical disease, or in experimental disease models.The identification of pathophysiological processes relevant to viral replication, viral infection; either in clinical disease, or in experimental disease models.The identification of pathophysiological pathways and processes relevant to the onset, maintenance, and progression of disease; either in clinical disease, or in experimental disease models.Studies that explore the impact of sex or gender, as well as young or advanced age on COVID-19 pathophysiology; either in clinical disease, or in experimental disease models.Studies specifically addressing coronavirus-host interactions, including the physiology of virus receptors on host cells, and the nature of the immune response of the host to SARS-CoV-2 and other human coronaviruses.Studies on genetic aspects of SARS-CoV-2 and other coronaviruses that relate to modulating the infectivity and other aspects of virus pathogenicity in in vitro, ex vivo, and in vivo (animal) models.Preclinical studies on the targeting of pathophysiological pathways relevant to onset, maintenance, and progression of disease, to reveal potential candidate novel disease management strategies.Preclinical studies exploring the impact of comorbidities that are modeled in experimental systems—including in vitro, ex vivo, and in vivo (animal) models—on the onset, maintenance, and progression of disease. Such comorbidities may include, but are not limited to, obesity, diabetes, combustible and e-cigarette smoking, and preexisting airways and other lung disease, as well as cardiovascular, renal, and hepatic disease.Clinical reports on unusual and interesting clinical observations in patients with COVID-19 that highlight unique or noteworthy physiological aspects of clinical disease. Manuscripts may be submitted as regular Research Articles or Rapid Reports. Additionally, Reviews, Mini-Reviews, or shorter Perspective articles, together with Case Reports and Letters to the Editor will be considered (Case Reports should be submitted directly to Physiological Reports). All manuscripts will receive expedited handling. Furthermore, all published articles addressing COVID-19 and its etiological agent SARS-CoV-2 are immediately made freely accessible by the American Physiological Society to everybody upon online publication. Please address any questions related to this Call for Papers to American Journal of Physiology–Lung Cellular and Molecular Physiology Editor-in-Chief, Dr. Rory E. Morty, at [email protected], and Physiological Reports Editor-in-Chief, Dr. Thomas R. Kleyman, at [email protected] The authors are supported by the Max Planck Society (R.E.M.); the German Center for Lung Research (Deutsches Zentrum für Lungenforschung; DZL) (R.E.M.), the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung; DZIF) (J.Z.); the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) through Excellence Cluster EXC2026 [390649896] (R.E.M.), Collaborative Research Center SFB1213 [268555672] Project A03 (R.E.M.) and SFB1021 [197785619] Projects A01 and B01 (J.Z.), Clinical Research Unit KFO309 [284237345] (R.E.M., Project P6; and J.Z., Project P3), and individual research grants Mo 1789/1-1 [160966624] and Mo 1789/4-1 [420759458] (R.E.M.); the State of Hessen Landesoffensive zur Entwicklung wissenschaftlich-ökonomischer Exzellenz Program through LOEWE Center DRUID (Project B02, J.Z.); and the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) through the Risikobewertung bei präpandemischen respiratorischen Infektionserkrankungen (RAPID) Program (J.Z.).DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONS R.E.M. and J.Z. drafted manuscript; edited and revised manuscript; and approved final version of manuscript.ACKNOWLEDGMENTS The authors thank all of the Editors of the American Journal of Physiology–Lung Cellular and Molecular Physiology for input into this Call for Papers.AUTHOR NOTESCorrespondence: R. E. Morty ([email protected]). Download PDF Back to Top Next FiguresReferencesRelatedInformationREFERENCES1. Abassi Z, Assady S, Khoury EE, Heyman SN. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. Am J Physiol Heart Circ Physiol 318: H1080–H1083, 2020. doi:10.1152/ajpheart.00215.2020. Link | Web of Science | Google Scholar2. Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies. Am J Physiol Lung Cell Mol Physiol. In press. doi:10.1152/ajplung.00097.2020. Link | Web of Science | Google Scholar3. Alimadadi A, Aryal S, Manandhar I, Munroe PB, Joe B, Cheng X. Artificial intelligence and machine learning to fight COVID-19. Physiol Genomics 52: 200–202, 2020. doi:10.1152/physiolgenomics.00029.2020. Link | Web of Science | Google Scholar4. Almeida JD, Berry DM, Cunningham CH, Hamre D, Hofstad MS, Mallucci L, McIntosh K, Tyrrell DAJ. Virology: coronaviruses. Nature 220: 650, 1968. doi:10.1038/220650b0.Crossref | Web of Science | Google Scholar5. Almeida JD, Tyrrell DA. The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J Gen Virol 1: 175–178, 1967. doi:10.1099/0022-1317-1-2-175. Crossref | PubMed | Google Scholar6. Beaudette FR, Hudson CB. Cultivation of the virus of infectious bronchitis. J Am Vet Med Assoc 90: 51–60, 1937.Google Scholar7. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH; WHO Strategic and Technical Advisory Group for Infectious Hazards. COVID-19: towards controlling of a pandemic. Lancet 395: 1015–1018, 2020. doi:10.1016/S0140-6736(20)30673-5. Crossref | PubMed | Web of Science | Google Scholar8. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 69: 382–386, 2020. doi:10.15585/mmwr.mm6913e2. Crossref | PubMed | Web of Science | Google Scholar9. de Groot RJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV, Perlman S, Poon L, Rottier PJM, Talbot PJ, Woo PCY, Ziebuhr J. Family Coronaviridae. In: Virus Taxonomy, edited by King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Amsterdam: Elsevier, 2012, p. 806–828.Google Scholar10. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 87: 7790–7792, 2013. doi:10.1128/JVI.01244-13. Crossref | PubMed | Web of Science | Google Scholar11. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14: 523–534, 2016. doi:10.1038/nrmicro.2016.81. Crossref | PubMed | Web of Science | Google Scholar12. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967–1976, 2003. doi:10.1056/NEJMoa030747. Crossref | PubMed | Web of Science | Google Scholar13. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LLM, Samborskiy DV, Sidorov IA, Sola I, Ziebuhr J; Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5: 536–544, 2020. doi:10.1038/s41564-020-0695-z. Crossref | PubMed | Web of Science | Google Scholar14. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 121: 190–193, 1966. doi:10.3181/00379727-121-30734. Crossref | PubMed | Web of Science | Google Scholar15. Huang C, Wang Y, L, J, Y, L, G, J, Cheng Z, J, Y, W, W, H, M, Y, H, L, J, Wang G, R, Z, Wang J, Clinical features of patients with 2019 novel coronavirus in Wuhan, Lancet 395: 2020. Crossref | PubMed | Web of Science | Google COVID-19: is the a Am J Physiol Lung Cell Mol Physiol. In press. Link | Web of Science | Google D, CS, Zaki S, S, C, W, AE, J, B, J, N, Group SARS Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 2003. Crossref | PubMed | Web of Science | Google Fouchier RA, M, van G, van D, JD, de van G, W, AE, Zambon R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, K, Osterhaus coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003. Crossref | PubMed | Web of Science | Google The of coronaviruses. Virus Crossref | PubMed | Web of Science | Google McIntosh a Top Microbiol | Google McIntosh K, Becker in organ of novel viruses from patients with respiratory disease. Proc 1967. Crossref | PubMed | Web of Science | Google MS, The WHO of emerging infectious diseases research and development Crossref | PubMed | Web of Science | Google Memish ZA, Perlman S, MD, Middle East respiratory syndrome. Lancet 395: 2020. Crossref | PubMed | Web of Science | Google R, COVID-19 and diabetes Am J Physiol In press. Link | Web of Science | Google N, G, G, E. SARS and MERS: are closely Microbiol In press. 2020. Crossref | PubMed | Web of Science | Google new respiratory disease of J Am Vet Med Assoc AM, and the cardiovascular Am J Physiol Heart Circ Physiol 318: 2020. Link | Web of Science | Google Tyrrell Almeida JD, Cunningham CH, Hofstad MS, McIntosh K, M, A, Coronaviridae. 5: Crossref | PubMed | Web of Science | Google Tyrrell Cultivation of a novel of virus in organ Med J 1: Crossref | PubMed | Google Tyrrell Cultivation of viruses from a of patients with Lancet 1: 1966. Crossref | PubMed | Web of Science | Google van der PubMed | Web of Science | Google the of the and its potential in COVID-19. Am J Physiol Lung Cell Mol Physiol. In press. | Web of Science | Google World Health A global research 2019 novel coronavirus World Health 2020, p. April World Health coronavirus situation report World Health 2020. April World Health coronavirus situation report World Health 2020. April World Health diseases for research and development in World Health 2020. April World Health SARS outbreak of 2003. World Health April World Health Severe acute respiratory syndrome Wkly 2003. PubMed | Google Zaki AM, van S, Osterhaus AD, Fouchier of a novel coronavirus from a with pneumonia in Saudi N Engl J Med Crossref | PubMed | Web of Science | Google risk of the to novel coronavirus 2019 Am J Physiol Physiol 318: 2020. Link | Web of Science | Google Z, M, Huang K, W, W, Z, Huang S, Z, M, J, and clinical of an early outbreak of severe acute respiratory syndrome (SARS) in J Med Microbiol 52: 2003. Crossref | PubMed | Web of Science | Google Poon LL, J, and cause of severe acute respiratory syndrome (SARS) in People's Republic of China, in 2003. Lancet 2003. Crossref | PubMed | Web of Science | Google N, D, Wang W, B, J, Huang B, W, R, Wang D, W, G, China Coronavirus and Research Team. A novel coronavirus from patients with pneumonia in China, N Engl J Med 2020. Crossref | PubMed | Web of Science | Google Ziebuhr J, Baric RS, Baker S, de Groot RJ, Drosten C, Gulyaeva A, Haagmans BL, Lauber C, Neuman BW, Perlman S, Poon LLM, Sola I, Gorbalenya 12 new species in the family Coronaviridae. Committee on Taxonomy of Viruses A, Perlman Middle East respiratory syndrome. Lancet Crossref | PubMed | Web of Science | Google Pathophysiology of COVID-19 and SARS-CoV-2 Infection for Papers: for the the of COVID-19 on Lung Health and and December | American Journal of Cellular and Molecular American Physiological Society Call for Papers on Physiology of R. E. Thomas R. Kleyman, Rory E. Morty, and November | American Journal of Cellular and Molecular health in November chronic disease, and in and Rory E. November | American Journal of Cellular and Molecular - A to | on 16, physiology of and the agents for February | Research health in November for adult and and chronic E. November | American Journal of Cellular and Molecular the Program of the American Journal of Cellular and Molecular and Rory E. July | American Journal of Cellular and Molecular | it how it and how it in | in is there a for as a November 2020 | in the health in November adult and and chronic disease in and Rory E. November 2020 | American Journal of Cellular and Molecular and Thomas and 2020 | American Journal of Cellular and Molecular Lung 2020 at the Journal of Physiology and the American Journal of Cellular and Molecular and Rory E. 2020 | American Journal of Cellular and Molecular of in COVID-19 and June 2020 | American Journal of Cellular and Molecular in the the April 2020 | - Journal of 27, from this 2020 the American Physiological April 2020 April 2020 online May 2020 in May 2020 more by on citations how this has been at how a scientific has been by the of the a classification it or the and a in which the was more by on for Papers: The pathophysiology of COVID-19 and SARS-CoV-2 E. Morty, American Journal of Physiology - Lung Cellular and Molecular for Papers: Physiology and American Journal of Physiology - and American Journal of Physiology - Lung Cellular and Molecular for in SARS-CoV-2 American Journal of Physiology - Lung Cellular and Molecular pathophysiology of acute lung injury and clinical Journal of with in the to by Medical of in advanced final from the to by Medical in patients with an a to by Medical for for to by Medical in patients with and cardiovascular to by Medical by

Topics & Concepts